Collate Raises $95M at Near-Unicorn Valuation for Life Sciences AI

Just 17 months after launching, Collate has raised $95 million at a valuation approaching $1 billion for its AI platform that automates life sciences documentation. Redpoint Ventures led the Series B round, bringing the San Francisco startup's total funding to $125 million.

The company, founded by two-time entrepreneur and former Y Combinator partner Surbhi Sarna alongside Nate Smith, addresses a critical bottleneck in pharmaceutical and biotech development: the massive volume of paperwork required for regulatory filings, clinical trials, and product development. Some regulatory submissions can exceed 10,000 pages, creating delays that slow the path from drug development to patient access.

Why it matters

Life sciences companies face documentation requirements that directly impact how quickly new therapies reach patients. By reducing document preparation time from seven months to one month or less in some cases, AI automation could meaningfully accelerate drug development timelines. The rapid customer adoption—50 clients including major pharmaceutical companies and publicly traded biotech firms within a year—signals the industry views this as an urgent operational priority rather than an experimental technology.

From seed to near-unicorn in under two years

Collate's trajectory reflects both the maturity of large language models and the founders' track records. Sarna previously sold her ovarian cancer detection startup NVision Medical to Boston Scientific for $275 million in 2018. Smith cofounded recruiting platform Lever before joining Y Combinator as a visiting partner.

Their credentials helped Collate raise $30 million in seed funding from Redpoint, First Round, and Conviction Partners at a valuation exceeding $100 million—before the company had a commercial product or customers. The startup signed its first customer in May 2025.

Accuracy and safety guardrails

Collate reports accuracy rates above 90 percent and often near 97 percent, with time savings ranging from 50 to 90 percent compared to manual processes. The platform requires human verification before documents can be exported, a safeguard Sarna describes as essential for patient safety even if it limits pure automation.

Redpoint partner Satish Dharmaraj, who led the investment, believes life sciences documentation represents an even larger market opportunity than legal AI, where Harvey recently reached an $11 billion valuation. The concentration of large pharmaceutical and medical device companies creates potential for rapid expansion within existing customer accounts.

Sarna predicts that within six to nine months, the majority of global life sciences companies will adopt AI for documentation workflows, whether through Collate or competitors. The company's early success suggests the market agrees with her assessment of urgency.

These details were first reported by Forbes in its InnovationRx newsletter.